Cyberonics Inc.

Daniel J. Moore became President and Chief Executive Officer of Cyberonics on May 1, 2007. During the first 12 months of his tenure, the Company resumed meaningful epilepsy revenue growth and returned to quarterly profitability after multiple years of losses. Under the direction of Mr. Moore and his senior management team, Cyberonics is focused on expanding its Vagus Nerve Stimulation (VNS) Therapy franchise for patients suffering from epilepsy. Mr. Moore joined Cyberonics from Boston Scientific where, since 1989, he held positions in sales, marketing and senior management in the United States and in Europe. In his last position at Boston Scientific, he was President, International Distributor Management. Prior to this, he was President, Inter-Continental, the fourth largest business unit of Boston Scientific with more than 1,000 global employees and revenues exceeding $700 million. Mr. Moore began his career with Procter and Gamble after graduating from Harvard College. He also earned an MBA from Boston University.

John A. Riccardi has served as Interim Chief Financial Officer since November 2006. Prior to assuming that role, he served as the Director, Financial Planning & Analysis since joining the Company in November 2005. In such position Mr. Riccardi led the financial planning, budgeting, forecasting, modeling, and analysis activities for the Company; he also managed the annual forecasting and planning procedures for the Company's budget process, and provided analytical measurement of the Company's financial performance. From May 1997 to November 2005 Mr. Riccardi was employed in several positions of increasing responsibility by Johnson & Johnson, Inc. a major producer and seller of products in the health care industry.

Richard L. Rudolph , M.D. joined Cyberonics in August 2001 as Vice President, Clinical and Medical Affairs and Chief Medical Officer. He has 20 years of pharmaceutical and medical device research and management experience in the neuroscience area. He has authored and co-authored numerous publications. Prior to joining Cyberonics, Dr. Rudolph was Senior Director, Clinical Research and Development at Wyeth-Ayerst Research. During his 16-year career at Wyeth-Ayerst, Dr. Rudolph was responsible for numerous clinical studies and research on Effexor(R) (venlafaxine hydrochloride) and Effexor(R) XR, a leading brand of medication for the treatment of patients with depression and generalized anxiety disorder.

David S. Wise joined Cyberonics in September 2003, as Vice President and General Counsel. He was appointed Secretary of Cyberonics in November 2003. He has over 20 years of experience in intellectual property, business development and legal affairs in private practice and in corporate practice in the medical device industry. Prior to joining Cyberonics, he was Group Vice President and General Counsel at Centerpulse USA, Inc. (formerly Sulzer Medica), a medical technology company specializing in orthopedic products recently acquired by Zimmer Holdings, Inc. from 1994 to 2003. Prior to Centerpulse, he spent 12 years in private practice focused on intellectual property and commercial litigation.

Milton M. Morris, Ph.D. joined Cyberonics as Vice President, Research & Development in January 2009. He joined Cyberonics from InnerPulse Corporation, a privately held cardiology-focused medical technology company in the Research Triangle Park (North Carolina), where he served as Director, Program Management and Operations since November 2007. Prior to InnerPulse, Dr. Morris was employed by Guidant Corporation and its successor, Boston Scientific Corporation. Over a period of 11 years, he held several positions including Senior Research Engineer; Manager, Research & Development; Director, Research & Development; and Director, Marketing. Dr. Morris is named as an inventor on 15 patents and an author on 19 publications, abstracts and scientific presentations.

Randal L. Simpson joined Cyberonics in 1998 and has served in various manufacturing management positions until October 2003 when he became Vice President, Operations. Prior to that, he served in the positions of Director, Manufacturing, Director, Materials and Sr. Director of Operations for Cyberonics. Prior to his joining Cyberonics, Mr. Simpson was employed by Intermedics, as Manager of Manufacturing. Mr. Simpson has over 20 years of manufacturing experience with over 14 years of experience in the medical device industry.

Alan Olsen has been an independent business consultant for the past 8 years and serves on the board of several public, private and charitable organizations. Mr. Olsen has over 28 years of medical device sales and marketing experience at Smith & Nephew Richards, Danek Medical and Sofamor Danek Group. He was founder and President of Danek Medical, a pioneer in the spinal fixation device market, which later became part of Sofamor Danek Group. He served as a Director of Sofamor Danek Group from 1985 to 1993.